Voyager Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss
Voyager Therapeutics, Inc. (VYGR) reported Debt Securities, Available-for-sale, Unrealized Loss of $66.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2018-03-14
- Voyager Therapeutics, Inc. debt securities, available-for-sale, unrealized loss for fiscal 2016 was $66.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|
| 2016-12-31 | $66.00K 10-K · filed 2018-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |